To include your compound in the COVID-19 Resource Center, submit it here.

Months after investment, Bayer strikes option deal with Dewpoint in CV, women’s health

Less than a year after Leaps by Bayer invested in biomolecular condensates company Dewpoint, the corporate VC’s parent company has struck an option deal that broadens its access to the start-up’s technology.

Bayer AG (Xetra:BAYN) will hold an option to obtain exclusive, worldwide rights to a specific number

Read the full 475 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers